Drug-eluting bead transarterial chemoembolization is an effective downstaging option for subsequent radical treatments in patients with hepatocellular carcinoma: A cohort study - 27/10/20
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Highlights |
• | 59.4% unresectable HCC patients had successful down-staging after DEB-TACE, and followed radical treatment reached CR of 81.3%. |
• | CNLC stage (IIb vs. IIa) was an independent factor for non-successful down-stating in unresectable HCC patients. |
• | Successful down-staging was correlated with longer PFS and OS, and was an independent factor for increased OS in unresectable HCC patients. |
Abstract |
Background |
This study aimed to investigate the potential of drug-eluting bead transarterial chemoembolization (DEB-TACE) as downstaging therapy for subsequent radical treatment in patients with hepatocellular carcinoma (HCC).
Methods |
Totally, 32 patients with unresectable HCC were enrolled, then they received DEB-TACE for down-staging therapy followed by radical treatments (surgery, radiofrequency ablation or microwave ablation). The rate of successful down-staging, treatment response (after DEB-TACE and radical therapy), alpha-fetoprotein (AFP), progression-free survival (PFS) and overall survival (OS) were assessed.
Results |
After down-staging therapy with DEB-TACE, successful down-staging rate was 59.4%. With the followed radical treatment, the complete response was 81.3%. Subsequent analysis indicated that CNLC stage (IIb vs. IIa) was an independent risk factor for successful down-staging. Furthermore, AFP level presented a declined trend throughout the time points (before DEB-TACE, after DEB-TACE, and after radical treatment). Additionally, 1-year, 2-year and 3-year accumulating PFS were 68.8%, 40.6% and 31.3%, respectively; 1-year, 2-year and 3-year accumulating OS were 84.4%, 71.9% and 53.1%, respectively. Kaplan-Meier curves exhibited that successful down-staging was correlated with longer PFS and OS, then further Cox’s regression analysis verified that successful down-staging was an independent factor for predicting increased OS but not PFS. Besides, child-Pugh stage (B vs. A), CNLC stage (IIb vs. IIa) and AFP abnormal after radical treatment were independent factors for decreased PFS or OS.
Conclusions |
DEB-TACE has potential as an additionally effective down-staging therapy for radical treatments, and successful down-staging treatment by DEB-TACE associates with favorable survival profiles in patients with unresectable HCC.
Le texte complet de cet article est disponible en PDF.Abbreviations : HCC, RFA, MWA, TACE, TACI, PEI, cTACE, DEB, CNLC, BCLC, PTA, AFP, PS, MRI, CR, CT, PR, SD, PD, ORR, DCR, SD
Keywords : Hepatocellular carcinoma, Drug-eluting bead transarterial chemoembolization, Down-staging, Treatment response, Survival profiles
Plan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?